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Cognition and Immunity: Antibody Impairs Memory
As patients with SLE live longer, many experience CNSCzeslawa Kowal,1 Lorraine A. DeGiorgio,3
Tsukasa Nakaoka,2 Hoby Hetherington,2 manifestations of disease. A recent consortium defined
19 syndromes, each of which constitutes a manifesta-Patricio T. Huerta,4 Betty Diamond,1
and Bruce T. Volpe3,* tion of neuropsychiatric (NP) lupus (American College of
Rheumatology, 1999). The most pervasive is progressive1Department of Microbiology and Immunology
2 Department of Radiology cognitive impairment (Denburg and Denburg, 1999),
which does not obviously correlate with disease activityDepartment of Physiology and Biophysics
Albert Einstein College of Medicine or with medication regimens (Brey et al., 2002; Carbotte
et al., 1986; Hanly et al., 1992; Hay et al., 1992; KozoraBronx, New York 10461
3 Department of Neurology and Neuroscience et al., 1996; Leritz et al., 2000).
NR2A and 2B are polypeptide chains that associateThe Burke Medical Research Institute
Weill Medical College of Cornell University with the NR1 polypeptide to form an NMDA receptor
(Ozawa et al., 1998). The natural ligand for these NMDA785 Mamaroneck Avenue
White Plains, New York 10605 receptors is glutamate. We recently identified a subset
of anti-DNA antibodies in SLE patients that binds both4 Center for Neural Science
New York University NR2A and 2B subunits by virtue of binding a pentapep-
tide consensus sequence present in both of these pro-4 Washington Place
New York, New York 10003 teins (DeGiorgio et al., 2001; Gaynor et al., 1997; Sharma
et al., 2003). These antibodies cause apoptosis of neu-
rons in vitro in human fetal brain cultures and in vivo
following direct injection into mouse brain. Furthermore,
antibodies with crossreactivity to DNA and NR2 wereSummary
present in the cerebrospinal fluid (CSF) of three patients
with SLE who experienced cognitive decline (DeGiorgioPatients with lupus (SLE) experience progressive cog-
nitive loss without evidence of CNS vascular disease et al., 2001).
Studies of brain pathology in lupus-prone strains ofor inflammation. SLE patients produce anti-DNA anti-
bodies that crossreact with NMDA receptors and are mice are difficult because the mice make a broad spec-
trum of autoantibodies and have infiltrating inflamma-capable of mediating excitotoxic death. We now show
that mice induced by antigen to express these anti- tory cells in the brain (Kier, 1990). BALB/c mice immu-
nized with the DNA peptide mimotope arrayed as anbodies have no neuronal damage until breakdown of
the blood-brain barrier occurs. Following administra- octamer on a polylysine backbone (MAP-peptide) de-
velop crossreactive anti-ds DNA and anti-NR2 antibod-tion of lipopolysaccharide (LPS) to immunized mice,
antibodies gain access to the brain. They bind pref- ies (Gaynor et al., 1997; Putterman and Diamond, 1998).
This model affords the opportunity to examine whether,erentially to hippocampal neurons and cause neuronal
death with resulting cognitive dysfunction and altered and under what conditions, these antibodies might
cause brain pathology and cognitive dysfunction. It per-hippocampal metabolism on magnetic resonance spec-
troscopy. Memantine, an NMDA receptor antagonist, mitted us to examine the effect of a systemic antibody
response without confounding causes of brain damagegiven prior to LPS administration, prevents neuronal
damage. Thus, systemic immune responses can cause and provided an opportunity to study the potential thera-
peutic use of NMDA receptor antagonists.cognitive impairment in the absence of an inflamma-
tory cascade, implicating the immune system in yet
another arena of human pathobiology. Furthermore, Results
NMDA receptor antagonists prevent antibody-medi-
ated damage and may constitute a new approach to Anti-NR2 Antibodies Caused Brain Injury
therapy in SLE. Only when There Was an Abrogation
of the Blood-Brain Barrier
Introduction All mice immunized with MAP-peptide developed high
titered anti-peptide antibodies and anti-DNA antibodies
SLE is characterized by the production of autoantibod- 9 weeks after immunization, while those mice immu-
ies, especially anti-nuclear antibodies. These antibodies nized with the polylysine backbone only (MAP-core)
contribute to several disease manifestations. Autoanti- developed no specific anti-peptide or anti-dsDNA anti-
bodies can mediate renal damage, hematological abnor- bodies (Figure 1). The titers of anti-peptide reactivity
malities, serositis, skin disease, and thrombosis (Hahn were approximately 2-fold greater than the titers of anti-
and Tsao, 2002). Antibodies that bind to double stranded DNA reactivity, with approximately 60 g/ml of anti-
(ds) DNA are present in affected glomeruli, skin, and peptide antibody present in the serum.
serosal surfaces in lupus patients (Hahn, 1998; Winfield Histopathological examination of the brains, however,
et al., 1977). revealed no neuronal damage, no infiltration of inflam-
matory cells, and no immunoglobulin deposition in the
cortex or hippocampus (Figures 2A and 2B). A small*Correspondence: bvolpe@burke.org
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3A) compared to MAP-core immunized mice (Figure 3B).
There was no neuronal loss in the hippocampus of mice
immunized with MAP-peptide but not exposed to LPS
(Figure 3C). Quantitative analysis showed a 30% loss of
pyramidal neurons in the CA1 region of the hippocam-
pus compared to MAP-core immunized mice; there was
no incremental damage in mice examined 30 days after
the insult (Figure 3D), consistent with a restored integrity
of the BBB. Damage remained selective for hippocam-
pal neurons.
Magnetic Resonance Spectroscopy Provides In Vivo
Confirmation of Neuronal Dysfunction
Neuro-imaging techniques have been developed to
gather information about brain disease antemortem.
Magnetic resonance imaging (MRI) of the brain provides
evidence for structural lesions, while magnetic reso-
nance spectroscopic imaging (MRSI) provides images
of major brain metabolites, including N-acetyl aspartate
(NAA), which is synthesized only in neuronal mitochon-
dria (Goldstein, 1969) and found only in neurons (Urenjak
et al., 1992). NAA and the ratio of NAA/Creatine (NAA/
Cr) have been extensively used in studies of the human
brain to identify regions of neuronal loss/damage (Heth-
erington et al., 1995; Hugg et al., 1993). Abnormal NAA/Figure 1. Mice Immunized with MAP-Peptide Produce Anti-Peptide,
Cr ratios can be seen in the presence or absence ofAnti-DNA Antibodies
detectable structural change measured by MRI (Chu etTiters of antibody to (A) DWEYS (n  number of mice  10) or (B)
dsDNA (n  10) in serum of mice immunized with MAP-peptide or al., 2000; Kuzniecky et al., 1997). Mice immunized with
MAP-core (polylysine backbone). MAP-peptide or with MAP-core and treated with LPS
were examined 30 days after LPS exposure and after
behavioral assessment (see below). Both groups of
mice displayed normal MRIs (data not shown) and hadamount of antibody was present around the circum-
comparable hippocampal volume by quantitative mor-ventricular organs where the blood-brain barrier (BBB)
phology. Representative images and spectrum from ais leaky but was insufficient to cause neuronal damage.
MAP-core immunized mouse are shown in Figure 4A.Presumably, an intact BBB prevented the transport of
Representative spectra from a MAP-peptide immunizedantibody from the systemic circulation into the brain.
mouse with anti-NR2 antibody and a MAP-core immu-It has previously been shown that LPS can cause a
nized mouse with no anti-NR2 antibody are shown intemporary opening of the BBB and yet does not cause
Figure 4B. Mice with anti-NR2 antibody displayed de-brain pathology (Xaio et al., 2001). LPS caused diffuse
creased hippocampal NAA/Cr ratios (Figure 4C), but nor-IgG staining in the brain of an unimmunized BALB/C
mal ratios in the thalamus (p  0.3; data not shown).mouse (Figure 2C). BALB/c mice immunized with either
Thus, it was possible to obtain in vivo evidence of neu-MAP-peptide or MAP-core were also given LPS. Seven
ronal loss/damage in this model, to demonstrate selec-days later, MAP-core immunized mice lacking anti-NR2
tive vulnerability of hippocampal neurons, and to docu-antibody displayed diffuse IgG immunoreactivity through-
ment that the noninflammatory loss of neurons presentout the brain, similar to that seen in LPS-treated, unim-
in this model can be detected by MRSI.munized mice (Figure 2D). In contrast, MAP-peptide
immunized mice producing anti-NR2 antibody showed
intense IgG deposition preferentially in hippocampal Mice Immunized with Peptide and Treated
with LPS Display Poor Memory Functionneurons, which express high-density NR2 (Figure 2E).
Only in these mice did IgG bind to cell bodies. Confocal The hippocampus and the function of NMDA receptors
are crucial in learning and memory (Sakimura et al., 1995;microscopy was used to show that IgG deposition colo-
calized with NR2 immunoreactivity (Figures 2G–2I). Tsien et al., 1996); mice with a deletion of NR2 display
impaired cognition (Fleischmann et al., 2003; SprengelMice were examined at intervals from 2 days to 30
days following LPS administration. There was no com- et al., 1998). Since we were able to demonstrate a prefer-
ential loss of hippocampal neurons and a selective al-plement deposition (data not shown) and no infiltrate
of blood-derived cells or recruitment of microglia or teration in hippocampal NAA/Cr ratios in mice with both
anti-NR2 antibody and a breach of the BBB, we exam-astrocytes in the brains of either group of mice at any
time. Table 1 shows that IgG staining decreased over ined whether these mice displayed a behavioral pheno-
type, particularly in hippocampal-dependent perfor-time in the hippocampus in MAP-peptide immunized,
LPS-treated mice, demonstrating a restoration of the mance. MAP-peptide immunized and LPS-treated mice
and MAP-core immunized and LPS-treated mice hadBBB following the initial insult.
At 7 days after LPS administration, there was clear comparable reflexes, strength, basal muscle tone, and
sensorimotor skills (data not shown; Crawley, 2000; Ir-neuronal loss in MAP-peptide immunized mice (Figure
SLE Antibodies Cause Neuron Death and Memory Loss
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Figure 2. Anti-NR2 Antibodies, in Conjunction with an Opening of the BBB, Lead to Neuronal Damage
(A) A representative Nissl-stained coronal section through the CA1 region of the hippocampus from a MAP-peptide immunized mouse not
treated with LPS shows normal pyramidal neurons and preserved cytoarchitecture (n  6; 5). The asterisk denotes the region depicted in
the inset (40).
(B) There is no immunoglobulin deposition present in these mice (n  6).
(C) In unimmunized mice given LPS, there is diffuse IgG staining 7 days after LPS exposure. There is no staining of cell bodies.
(D) In animals immunized with MAP-core and treated with LPS (n  6), brain sections displayed diffuse IgG immunoreactivity 7 days after
LPS exposure, again with no staining of cell bodies.
(E) In contrast, animals treated with LPS after MAP-peptide immunization displayed IgG deposition intensely concentrated in neurons in the
CA1 region of the hippocampus (n  6).
(F) Secondary antibody alone did not stain neurons.
(G–I) Confocal images of tissue from mice immunized with MAP-peptide and treated with LPS.
(G) Hippocampal neurons are stained with FITC-labeled anti-mouse IgG.
(H) In the same section, hippocampal neurons are stained with anti-NR2A antibody (secondary is rhodamine labeled; NR2B was similar, data
not shown).
(I) Overlap of (G) and (H) (yellow signal) demonstrate colocalization of endogenous antibody and staining by anti-NR2 antibody.
win, 1968). There were no statistical differences on tasks rotarod, the plus maze, the black-white alley, and the
object recognition task) (Ennaceur and Delacour, 1988).measuring balance on a rotating drum, anxiety, and ex-
ploration of familiar and novel objects (data not shown, The MAP-peptide immunized and LPS-treated mice,
however, displayed clear performance deficits on taskssee Experimental Procedures for details of accelerating
Table 1. Regional Distribution of Neurons Stained with IgG
Immunization
and Treatment Survival Animals Hipp Ctx Striatum Thalamus Hypothal sbF/CVO
MAP-peptide LPS 5 d 4 100 (24) 27 (77) 5 (75) 34 (28) 75 (18) 100 (15)
MAP-core LPS 5 d 1 0 (6) 0 (20) 0 (8) 0 (4) 0 (4) 100 (4)
MAP-peptide LPS 10 d 8 34 (32) 25 (32) 0 (32) 3 (32) 22 (32) 100 (8)
MAP-core LPS 10 d 4 0 (16) 0 (16) 0 (16) 0 (16) 0 (16) 100 (12)
MAP-peptide LPS 30 d 8 16 (32) 0 (32) 0 (32) 9 (32) 22 (32) 100 (16)
MAP-core LPS 30 d 4 0 (32) 0 (32) 0 (32) 0 (32) 0 (32) 100 (4)
Each positive section had neurons that were IgG immunoreactive. Shown are the percent of sections with immunoreactive neurons (number
of sections analyzed). Survival describes the days between the second LPS injection and sacrifice. Abbreviations: hipp, hippocampus (CA1,
2, and 3, and dentate gyrus); ctx, cortex (retrosplenial, M1, M2, S1, S2, amygdala, and piriform); striatum, ventral pallidum; thalamus, lateral
dorsal and paraventricular thalamus; hypothal, hypothalamus; sbF/CVO, subfornical and circumventricular organs.
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Figure 3. Quantitative CA1 Neuron Loss Oc-
curs in Mice with Anti-NR2 Antibodies and a
Breach in the BBB
(A–C) Nissl-stained brain sections from MAP-
peptide and MAP-core immunized mice, sac-
rificed 7 days after LPS administration, and
from MAP-peptide immunized mice given no
LPS, respectively.
(D) Quantitative morphometric analysis in
LPS-treated MAP-peptide and MAP-core im-
munized animals 7 days (n  8) and 30 days
(n  10) after LPS demonstrated that MAP-
peptide immunized animals sustained a sig-
nificant loss of CA1 hippocampal neurons
(p 0.0001 for both groups). Neuron number
is expressed as the density of neuron/105m3
(modified from Cho et al., 1997; Volpe et al.,
1998); 7 day survival, mean  SEM, MAP-
peptide  16.38  .56; MAP-core  24.47 
.71 neurons/105 m3; 30 day survival, MAP-
peptide  16.66  .45, MAP-core 
26.49  1.4.
that depend on the integrity of the hippocampus. They nized mice were significantly impaired in learning this
task (Figure 5C). This selective impairment in learningperformed at chance in a T-maze task that required
that they recognize which arm of the maze they had and memory function is consistent with the neuropsychi-
atric studies of lupus patients who demonstrate poorpreviously explored (Figure 5A; Deacon et al., 2002). In
the Morris water maze task, mice are required to find performance in verbal and spatial memory tasks (Brey
et al., 2002; Denburg and Denburg, 1999).a submerged platform (Morris et al., 1986). All mice
showed a gradual decrease in the time taken to find
the hidden platform as training proceeded, but MAP- Memantine Protects from Antibody-Mediated Injury
In order to confirm that the damage that occurred in thepeptide immunized mice repeatedly spent more time
than MAP-core immunized mice exploring regions of brains of these mice was due to engagement of NMDA
receptors by antibody, similar to glutamate-induced ex-the maze that did not contain the platform (Figure 5B,
probe 2; T indicates target/platform sector). We also citotoxicity, we treated MAP-peptide immunized mice
with memantine, an NMDA receptor antagonist. Meman-performed a newly designed water maze training proto-
col that tests for the ability to learn the location of the tine is a potent noncompetitive inhibitor of NR2A- or
NR2B-containing receptors (Avenet et al., 1997; Danyszsubmerged platform when the location is periodically
changed (Chen et al., 2000). The MAP-peptide immu- and Parsons, 2003). Mice were given memantine by in-
Figure 4. Magnetic Resonance Spectroscopy Shows an Altered NAA/Cr Ratio
(A) Shown are a representative T1-weighted anatomical image from a MAP-core immunized, LPS-treated mouse on the left, and spectroscopic
imaging grid identifying the hippocampus from the same mouse on the right. A representative spectrum from the hippocampus is shown below.
(B) Shown are spectra from the hippocampus and thalamus of a MAP-peptide and MAP-core immunized, LPS-treated mouse.
(C) Shown are the hippocampal NAA/Cr ratios for three MAP-peptide and MAP-core treated mice (A; mean  SEM, MAP-peptide  0.75 
.09, MAP-core  0.99  .08). Anatomical images were used to determine the hippocampal voxels bilaterally. The values represent mean 
SD for the hippocampal voxels in each animal on an animal by animal basis. There is a significant reduction in NAA/CR in the hippocampus
of the MAP-peptide immunized, LPS-treated mice in comparison to the MAP-core immunized, LPS-treated mice (p  0.01).
SLE Antibodies Cause Neuron Death and Memory Loss
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Figure 5. Mice with Anti-NR2 Antibodies and
Given LPS Develop Memory Abnormalities
(A) MAP-peptide treated mice were impaired
on a spatial working memory task in the
T-maze. They performed roughly at chance
throughout the test (MAP-peptide, 52.6% 
4.0%, MAP-core, 71.7%  4.2% alternations
during all trials, p 0.0027). For blocks 3 and
4, MAP-core treated mice performed 75%
alternations; in each of these blocks, their
performance was significantly higher when
compared to MAP-peptide treated mice
(**p  0.002, t test).
(B) MAP-peptide treated mice showed a defi-
cit in spatial reference memory but not in spa-
tial navigation, as assessed by the Morris wa-
ter maze task. The left panel shows the
latency to reach the hidden platform (a mea-
sure of spatial learning), whereas the right
panel shows the time spent in each sector
during the probe trials (a measure of spatial memory). In this task, animals were trained to find a hidden platform inside a circular pool, filled
with opaque water. Mice had to use distal cues as spatial guides. First, animals underwent 3 blocks (4 trials/block) with a large hidden platform
(diameter, 24 cm). During each trial, a mouse was given a maximum of 90 s to find the platform. The 12 trials were followed by a “probe” test
(Probe 1), in which each mouse swam for 60 s with the platform removed from the pool. Mice that had memorized the position of the platform
within the pool would preferentially swim in that area, which we call the “trained” sector. Thereafter, mice underwent 6 blocks with a small
hidden platform (diameter, 16 cm), followed by Probe 2. The left panel shows that the MAP-peptide mice decreased their latency and were
able to find the hidden platform at the same rate that MAP-core mice (no statistical difference between groups). However, the right panel
shows that MAP-peptide immunized mice displayed reduced exploration of the trained sector, a clear indication of spatial memory deterioration
(Probe 2, MAP-peptide, 35.1%  3.5%, MAP-core, 48.4%  3.8% time in trained sector; *p  0.018, t test). Abbreviations for sectors: T,
trained; O, opposite; L, left; R, right.
(C) MAP-peptide treated mice were impaired in spatial flexibility, as assessed by the training-to-criterion task. The left panel shows the scheme
of the task: if a mouse found the hidden platform in location N in less than 20 s for 3 consecutive runs, then a new location (N  1) was
selected. Mice were trained to criterion on 5 consecutive locations. The right panel shows that MAP-peptide immunized mice were significantly
poorer than MAP-core immunized mice in their ability to learn a given location (MAP-peptide, 12.6 1.2, MAP-core, 6.9 0.4 trials-to-criterion
[inclusive], p  0.0000017). For locations 3, 4, and 5, MAP-peptide immunized mice were significantly different (***p  0.0001, t test) when
compared to MAP-peptide treated mice.
traperitoneal injection, just before and after administra- glutamate, the natural ligand for this receptor, the anti-
bodies were shown to mediate an apoptotic, excitotoxiction of LPS in order to ensure that the drug was present
when the neurons were exposed to antibody. Mice were neuron death in vitro and also when injected directly
into the brain. This injury was inhibited by MK-801, asacrificed 2 and 5 days after LPS administration, and at
both survival intervals, histology was normal in meman- noncompetitive inhibitor of NMDA receptors (DeGiorgio
et al., 2001). It was not evident, however, from our initialtine-treated mice. To determine whether there was evi-
dence for neuronal damage, brain sections were stained studies whether these antibodies could cause brain
damage when present in the systemic circulation. Wewith fluoro-jade, which identifies stressed neurons, and
with antibody to activated caspase-3, which identifies therefore undertook an analysis of BALB/c mice immu-
nized with MAP-peptide. These mice produce high titersneurons in a late stage of apoptosis. Brains of mice
not receiving memantine displayed fluoro-jade reactivity of anti-DNA, anti-NR2 antibody. Because BALB/c mice
have no spontaneous brain pathology, we could ex-and stained positive for activated caspase in hippocam-
pal neurons at both time points (Figure 6). Memantine amine the effects of antibody in the absence of any
other pathological process. Neuropathology required aadministration completely protected hippocampal neu-
rons from injury, with no detectable fluoro-jade reactivity breach in the integrity of the BBB. Thus, serum titers of
anti-DNA, anti-NR2 crossreactive antibody alone in SLEand no evidence of activated caspase, and did not
merely delay the effects of antibody (data not shown). patients cannot be expected to correlate with antibody-
mediated brain damage. This observation also supportsThus, we were able to confirm that anti-NR2 antibody
was responsible for tissue pathology and to show that a recent study suggesting that the exposure of the brain
to antibody is carefully regulated (Schlachetzki et al.,NMDA receptor antagonists offer a potential therapeu-
tic strategy. 2002). While receptors for IgG and IgA (FcRn) usually
transport immunoglobulin from the circulation to the
tissue, in cerebral endothelium they display a polarityDiscussion
such that immunoglobulin is transported from tissue
to circulation.Autoantibodies are a central feature of SLE, but how
It is well appreciated that infection is one circum-they mediate tissue damage remains an area of active
stance leading to an abrogation of the BBB, and bacte-investigation. We previously showed that a subset of
rial LPS appears to be a causative agent. Therefore, weanti-DNA antibodies that is prevalent in patients with
administered LPS to mice with a high titered anti-NR2renal disease could bind to subunits of the NMDA recep-
tor (DeGiorgio et al., 2001; Gaynor et al., 1997). Like antibody response to determine whether incremental
Immunity
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Figure 6. Memantine Treatment Blocks Hippocampal Damage in MAP-Peptide Immunized LPS-Treated Animals
Animals immunized with MAP-peptide and treated with LPS and memantine (n  6) had normal histology 2 days after LPS treatment (A), and
no immunoreactivity with activated caspase-3 (B), and no fluoro-jade reactivity (C) in the hippocampus. Animals immunized and treated with
LPS and not given memantine had abnormal hippocampal histology (cresyl violet; D) with caspase-3 immunoreactive (E) and fluoro-jade
positive neurons (F). All insets are 40.
cognitive impairment could occur due to infection, might occur as a consequence of disease activity, such
as cerebral vasculitis, but might also occur as a conse-rather than disease exacerbation. When LPS was ad-
ministered to the mice, there was preferential binding quence of infection, stress, catecholaminergic excess,
or nicotine exposure, all conditions known to abrogateof antibody in the hippocampus and consequent loss
of hippocampal neurons. One week following exposure the integrity of the BBB (Abdel-Rahman et al., 2002;
Esposito et al., 2002; Friedman et al., 1996; B.T. Hawkinsto systemic antibody, neuronal loss was evident, with
no increment in damage at a month following LPS expo- et al., 2003, Soc. Neurosci., abstract; Xaio et al., 2001).
Thus, this study provides a possible explanation for thesure. There was no evidence of either inflammatory cell
infiltrate or characteristic progressive neurodegenera- observation that cognitive decline in SLE does not paral-
lel disease activity (Leritz et al., 2000). The data alsotive change. While it has been reported that cytokines
can be toxic to neurons (Downen et al., 1999), the cyto- imply that there will not be a linear relationship between
serum antibody titer and CNS pathology. The neuronalkine milieu can be assumed to be the same in mice
with and without specific antibody, as control mice also damage and loss that occurs in this model is noninflam-
matory, consistent with the clinical observation that cog-received complete Freund’s adjuvant during the immu-
nization protocol and also received LPS. Thus, in these nitive impairment can be progressive in the absence of
CNS vasculitis or thrombosis. The data also demon-studies, antibody alone was sufficient to cause brain
pathology, and damage occurred only when the BBB strate that MRSI can be used to detect abnormalities
in neuronal metabolism that correlate with behavioralwas breached.
It is well documented in studies of both rodents and dysfunction. MRSI has previously been used to docu-
ment neuronal damage and loss in a model of Hunting-humans that loss of neurons in the hippocampus leads
to an impairment in memory function (Rempel-Clower ton’s disease (van Dellen et al., 2000) and a model of
scrapie (Chung et al., 2003). Mice expressing an N-ter-et al., 1996; Volpe et al., 1992; Volpe and Petito, 1985).
Global hypoxic ischemic injury selectively destroys hip- minal fragment of the human huntingtin protein develop
a 26% decrease in the NAA levels and a 15% decreasepocampal neurons and leads to memory dysfunction
with relative preservation of other behaviors (Hirst and in neuron number in the corpus striatum; these mice
also display poor performance in the Morris water mazeVolpe, 1988; Volpe and Hirst, 1983). In humans, this
impairment can be subtle but devastating, so that af- (Murphy et al., 2000). Mice infected with scrapie show
a 50% decrease in NAA/Cr ratio in the hippocampusfected individuals may be unable to continue their pro-
fessional activities even as they compensate sufficiently and a 50% loss of neurons at 9 months postinfection.
In our study, we see a 27% decrease in hippocampalto carry out ordinary activities of daily living.
The data presented provide a model to explain cogni- NAA/Cr ratio and a 30% decrease in CA1 neurons in
the hippocampus. Thus, there is a strong correlationtive decline in SLE. The model requires the presence of
anti-DNA, anti-NR2 antibodies that are found in approxi- between NAA/Cr and neuron number. This demonstra-
tion of an MRSI abnormality in behaving mice also sug-mately 25%–50% of patients with SLE (Sharma et al.,
2003) and a breakdown in the BBB. This breakdown gests that it may be possible to test therapeutic interven-
SLE Antibodies Cause Neuron Death and Memory Loss
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LPS Treatmenttions in patients with SLE and obtain both in vivo imaging
LPS (E. coli, 055:B5, Sigma), at a dose of 3 mg/kg diluted in lactatedand behavioral studies to assess their efficacy.
Ringers solution to 0.3 mg/ml, was given as an i.p. injection toFinally, we show that an NMDA receptor antagonist
DWEYS or polylysine backbone immunized mice. The LPS treatment
can protect neurons from death. This serves to confirm was given twice, 48 hr apart at 4–8 weeks after the last immunization.
that it is the anti-NR2 antibodies that cause neuronal The histology, MRSI, and cognitive assays were performed at a
month after the LPS treatment.pathology and that the mechanism of death is excitotox-
Some of the mice were given i.p. injections of memantine hydro-icity. MK-801, which we previously showed could pro-
chloride (Sigma) at 5 mg/kg in Ringer’s solution 30 min prior to LPStect mice from neuronal injury after a direct injection of
administration and 24 hr after each LPS injection. Animals wereantibody into the brain, and memantine are noncompeti-
sacrificed 2 and 5 days after the second LPS injection.
tive inhibitors of NMDA receptors that bind to the NR2
receptor at a common site (Kashiwagi et al., 2002). In
Immunohistology
this study, we used memantine rather than MK-801 to To assess IgG deposition, hippocampal sections were incubated in
inhibit excitotoxicity, since memantine has recently horse anti-mouse IgG at a 1:200 dilution in 0.1 M PBS (pH 7.4) for
1 hr (Vector Laboratories, Burlingame, CA). Sections were incubatedbeen shown to retard the progression of Alzheimer’s
in avidin-biotin horseradish peroxidase complex at a 1:100 dilutiondisease in patients with moderate to severe symptoms
for 1 hr. Mouse IgG was visualized by diaminobenzidine (0.5 mg/ml)and can be taken long term without major side effects
in the presence of 0.03% H2O2. For detection of activated caspase-3,(Reisberg et al., 2003). Our data suggest the possibility of
tissue sections were rinsed in 0.1 M phosphate buffered saline (PBS,
a therapeutic role for memantine in SLE. It was recently pH 7.4) for 10 min, permeabilized for 15 min in 0.2% Triton X-100
reported that NR2B is present in extrasynaptic NMDA in the same buffer containing 2% bovine serum albumen (BSA),
rinsed 2 in 0.1 M PBS for 15 min. Nonspecific binding sites werereceptors and mediates an excitotoxic, apoptotic signal
blocked with 2% BSA in 0.1 M PBS for 1 hr. Sections were incubated(Hardingham et al., 2002). In contrast, both NR2A and
in rabbit anti-activated caspase-3 (1:200 in blocking solution, Phar-NR2B are present in synaptic receptors. Activation of
mingen, San Diego, CA) overnight at 4C. Sections were rinsed 2synaptic receptors is not excitotoxic. It may be that
in 0.1 M PBS, 1 in 0.1 M PB for 15 min each and were then
antibody has greater access to extrasynaptic receptors incubated for 45 min in donkey anti-rabbit IgG-Texas Red (1:200 in
or that a competition between death and survival signals 0.1 M PB, Jackson Immunochemicals, West Grove, PA). Prepara-
tions were rinsed 3 in 0.1 M PB for 45 min, mounted on gelatin-occurs. It can be anticipated that an inhibitor that inter-
coated slides, air-dried, and coverslipped with Cytoseal (Stephensacts specifically with the extrasynaptic NMDA receptors
Scientific, Kalamazoo, MI). Final preparations were evaluated on acomposed of NR1 and NR2B only would be an even
Zeiss Axiophot microscope fitted with an epifluorescent light sourcemore useful potential therapeutic agent.
and appropriate narrow pass filter sets. Photomicrographs were
Of general importance, these studies provide a model composited using Adobe Photoshop.
for an immunologically mediated, noninflammatory loss To assess colocalization of mouse IgG with NMDA receptor sub-
type 2A or 2B, hippocampal tissue was rinsed 2 in 0.1 M PBS andof cognitive function. That a systemic antibody response
nonspecific binding sites were blocked with 1% BSA. Sections werecan lead to cognitive decline or altered mental function
incubated in rabbit NR2A or NR2B antibody (1:2000 in blockingwithout brain inflammation is a new paradigm to explain
solution; Molecular Probes, Eugene, OR) overnight at 4C, followedaspects of neuropsychiatric lupus, which can now be
by a mixture of donkey anti-rabbit IgG-Rhodamine Red X and goat
tested in clinical studies. Moreover, it is highly likely anti-mouse IgG-FITC for 45 min at room temperature (each at 1:200
that this paradigm can explain other conditions in which in 0.1 M PB, Jackson Immunochemicals). Sections were mounted
on gelatin-coated slides, air-dried, and coverslipped with Cytosealbehavioral abnormalities also result from the penetration
(Stephens Scientific). Final preparations were evaluated on a Zeissof specific antibodies into brain tissue, and it provides
LSM 510 confocal microscope, using software from Zeiss (Thorn-a potential link between infections and vaccines and
wood, NY).altered mentation.
For fluoro-jade staining, tissue sections were mounted onto gelati-
nized slides and allowed to dry at room temperature. Slides were
immersed sequentially in 100% EtOH for 3 min, 70% EtOH for 1Experimental Procedures
min, dH2O for 1 min, 0.06% KMnO4 diluted in dH2O for 15 min, dH2O
for 1 min, 0.001% fluoro-jade aqueous staining solution containingImmunization Protocol
0.1% acetic acid for 30 min (HistoChem, Jefferson, AR), and rinsedBALB/c mice, 6- to 8-week-old females (Jackson Laboratory, Bar
3 times in dH20 for 1 min each. Preparations were dried overnight,Harbor, ME), were immunized intraperitoneally (i.p.) with 100 g of
rinsed twice in xylene, and coverslipped with CytoSeal (Stephensantigen, either MAP-DWEYS or MAP-Core (both from AnaSpec, San
Scientific).Jose, CA), per mouse, per immunization, in 100 l of saline. The
first immunization was performed using Complete Freund’s Adju-
Quantitative Morphologyvant (CFA); two or three boosts were given at bi-weekly intervals in
We modified our published techniques (Cho et al., 1997; Volpe etIncomplete Freund’s Adjuvant (IFA).
al., 1998) and developed an unbiased counting strategy (Coggeshall
and Lekan, 1996) based on the use of stereological methods and
the optical dissector (Gunderson, 1986). A 100  100 mm frame 10ELISAs
ELISAs were performed as described previously (Putterman and boxes on a side with its vertical axis perpendicular to the stratum
pyramidale was systematically passed along the entire length of theDiamond, 1998). In brief, the plates (Costar, 3690, Corning, Corning,
NY) were coated with DWEYS peptide at 15 g/l in 0.1 M NaHCO3 CA1 region. The CA1-CA2 border was identified by the change in
neuron shape and packing density. All sections were viewed under(pH 8.6) overnight at 4C, and double stranded (ds) calf thymus (CT)
DNA was dry coated at 100 g/l overnight at 37C. The plates were oil, 100. The counting frame was a 50  100 mm subsection of
the frame. Neurons were counted in the frame if part or all of thewashed and incubated with serum at indicated dilutions in 0.2%
BSA/PBS for 1 hr at 37C. The secondary antibody, goat anti-mouse nucleus was within the frame and not in contact with the left or
bottom border of the frame. For each animal, neurons in the rightIgG-AP, at 1:1000 dilution in 0.2% BSA/PBS was added for 1 hr at
37C or o/n at 4C. The assays were developed at room temperature and left stratum pyramidale were sampled from comparable regions
of the anterior dorsal hippocampus (Bregma 	3.2 mm) and theusing p-nitrophenyl phosphate disodium salt tablets (Sigma, St.
Louis, MO). posterior dorsal hippocampus (Bregma 	3.8 mm). There were 12
Immunity
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sections from each animal, each separated by 160 mm. We divided drum (ENV-576M, Med Associates Inc, St. George, VT), which was
accelerated from 4 to 40 rpm over the course of 5 min. The time atthe number of neurons by the total volume sampled to generate the
density of neurons in CA1. Mean neuron density was calculated for which each animal fell from the drum was recorded. A mouse re-
ceived 3 consecutive trials and the longest time on the drum wasMAP-peptide and MAP-core immunized, LPS-treated animals, the
left and right hippocampus, and for the anterior and posterior re- used for analysis.
The black-white alley was adapted from Deacon et al. (2002). Twogions and for animals sacrificed after 7 and 30 days. For the hippo-
campal volume estimates, consistent internal anatomic landmarks wooden boxes (each 60  9  30 cm, with one open end, one
painted black and the other white) were assembled so that their(for the anterior, the beginning of CA3; and for the posterior, the
posterior commissure) marked the anterior-posterior border. Coro- open ends faced each other, thus forming a 120 cm black-white
alley. A mouse was introduced in the black end and was left in thenal sectioning strategy occurred as for the neuron counting and the
area of the right and left hippocampus was measured digitally with alley for 1 min. We scored the initial latency to cross into the white
side, the number of crossings (four paws), and the time spent in theKS400 programs (Zeiss, Thornwood, NY). Volumes were calculated
based on the product of a mean area and tissue thickness and the white side.
Two-object recognition memory was tested in a chamber (25 cmnumber of sections in the defined anterior-posterior region.
long, 25 cm wide, 60 cm high) with open ceiling, constructed of
white plastic. It was illuminated from the top by a 40 W white bulb. AMRSI of Mouse Brain
CCD camera was also mounted on top and was used for videotapingSpectroscopic images of the mouse brain were acquired using a
behavior. The floor was covered with a thin layer of bedding. Before9.4T Varian INOVA system using a combination of an actively detun-
formal testing, each mouse was allowed to familiarize with the emptyable volume coil for transmission and a 10  8 mm elliptical surface
chamber for 3 sessions (5 min each over a period of 2 days). Acoil for reception. Animals were anesthetized and maintained on
single trial consisted of 3 phases: sample, delay, and choice. For2.5% isoflurane administered through a specially designed nose
the sample phase, mice were placed in the chamber and allowedcone. The animals were placed in a plastic head frame, securing
to explore two identical objects for a period of 5 min. For the delaythe head by teeth and ear bars.
phase, mice were placed in their home cage for 10 min. During thisAnatomical images were acquired using an inversion recovery
interval, test objects replaced sample objects. One of them wassequence TR/TIR 2.9/0.9 with 11 slices (0.5 mm thick) and a 24 
identical to those in the sample phase (“familiar object”) whereas24 mm FOV (128  128 resolution). 3D localized volumes (1  6 
the other was different (“novel object”). Extreme care was taken in8 mm) within the mouse brain were selected using an adiabatic
placing the objects in exactly the same positions occupied by therefocusing method (LASER) in combination with a broad-band semi-
sample objects. For the choice phase, mice were allowed to exploreselective excitation sequence. Spectroscopic images were acquired
for 5 min. Object exploration was scored when the mouse touchedby encoding over the selected voxel using a FOV of 24  24 mm
the object with the face (mouth, whiskers, and nose). Touching thewith 24  24 encodes resulting in an effective voxel size of 1 l.
object with any other part of the body while facing another directionThe data was acquired using a TR of 2 s with 2 averages resulting
was not counted as an exploration. After the experiment, tapes ofin an acquisition time of 38 min. Voxels spanning the hippocampi
the trials were revised and the exact time spent on each of thebilaterally were selected using the anatomical images. The data
objects was obtained.from each voxel were fit in the spectral domain and resonance
The T-maze task was adapted from Deacon et al. (2002). Theareas used for calculations of the NAA/Cr ratio. The mean value
apparatus consisted of an enclosed T-maze, each arm 30 cm longand standard deviation for NAA/Cr was then calculated for each
10 cm wide  29 cm high, made of white painted plastic. The sideanimal separately.
walls were angled at 110 (toward the outside). A removable central
partition extended 7 cm from the back of the T into the start arm,
Behavioral Assays dividing the choice area. In the first phase of the test, the central
An experimental group (MAP-peptide, n  12, MAP-peptide immu- partition was in place and the mouse navigated from the end of the
nized, LPS-treated) and a control group (MAP-core, n  15, MAP- start arm. After it entered a goal arm, it was confined there for 30
core or polylysine backbone immunized, LPS-treated) were studied. s (by blocking the entrance) before being returned to the start arm
Mice underwent the following sequence of tests: elevated plus- by the experimenter. During the delay, the central partition was
maze, behavioral screen, rotarod, black-white alley, two-object rec- removed. The second phase consisted of the mouse simply choos-
ognition memory, T-maze (working memory), Morris water maze ing between the two arms. The choice arm was the one the animal
(reference memory), and training-to-criterion. The mice were run in first entered with the whole body. Each mouse participated in 16
squads of 6–10 at a time by an experimenter who was “blind” with trials over 4 days; the minimum intertrial interval was 1 hr.
respect to their group assignment (3–5 animals of each group in The Morris water maze was used to test for spatial reference
a squad). memory (Morris et al., 1986). The apparatus consisted of a circular
The elevated plus maze consisted of two arms with walls (27 cm pool (160 cm diameter, opaque water at 20C  1C) surrounded
long, 8 cm wide, 30 cm high, painted black) and two open arms (30 by prominent visual cues. Mice were placed into the water facing
cm long, 4 cm wide, 0.5 cm high beading, painted white). The maze the side walls and allowed to swim until they found the hidden
was elevated 70 cm above floor level. A mouse was placed at the platform (top surface 1.5 cm below water level). The maximum trial
end of an enclosed arm and observed over a 5 min period. We duration was 90 s, with 20 s on the platform at the end of the trials.
measured the initial latency to enter an open arm (with the four Swim paths were monitored by video. The task was divided into
paws), the number of entries, and the total time spent in the open two phases: in the first, mice were trained to find a “large” hidden
arms. These parameters are known to be anxiety related (Contet et platform (diameter, 24 cm) for 12 trials (4 trials per day). After this,
al., 2001; Deacon et al., 2002). a first probe trial was performed: each mouse swam for 60 s with
The behavioral screen consisted of a total of 38 separate measure- the platform removed from the pool. The second phase consisted
ments, recorded for each mouse (modified from Crawley, 2000; of 24 trials, in which the mice found a “small” platform (diameter,
Irwin, 1968). Assessment started with observation in a cylindrical 16 cm). A second probe trial ensued at the end of training.
glass flask (height 15 cm, diameter 11 cm) followed by transfer to For the training-to-criterion task, mice were required to find five
an arena (55 33 cm). This was continued with manipulations using consecutive locations in the water maze. Each animal was trained,
tail suspension for measuring visual acuity, grip strength, body tone, for up to eight trials per day, to a performance criterion of three
and reflexes. Subsequently, the mouse was restrained in supine successive trials with an escape latency of less than 20 s before
position to record autonomic responses of skin color, limb tone, and being transferred to the next location on the next day (maximum
abdominal tone. Salivation and provoked biting were also recorded. trials was 40 for location 1, and 32 trials thereafter).
Measuring the righting reflex and negative geotaxis completed the
screen. Throughout the procedure, incidences of abnormal behav- Acknowledgments
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